Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-09-30 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
董事和高级管理人员所持公司股份及其变动管理制度（H股发行上市后适用）
Governance Information Classification · 95% confidence The document is titled '董事和高级管理人员所持公司股份及其变动管理制度' which translates to 'Management System for Shares Held and Changes by Directors and Senior Management'. It details rules and procedures regarding the holding and trading of company shares by directors and senior management, including compliance with laws, disclosure requirements, restrictions on trading periods, and reporting obligations. The content focuses on governance and internal rules related to directors' shareholdings and transactions, rather than financial results, audit opinions, or general regulatory announcements. It is not a report of share transactions (DIRS) but a policy or governance document outlining the management system for such transactions. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is about internal governance rules for directors and senior management shareholding and trading.
2025-09-30 Chinese
独立董事工作制度（H股发行上市后适用）
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and is dated September 2025. It details the rules, responsibilities, nomination, election, and working conditions of independent directors for the company 科兴生物制药股份有限公司. The content focuses on governance structure, director duties, qualifications, and procedural rules rather than financial data or report results. There is no indication that this is a report of financial performance, audit, or earnings. It is a governance-related document outlining internal rules and practices for independent directors, consistent with governance information filings. The document length is substantial (8634 characters), indicating it is the full policy text, not a brief announcement or summary. Therefore, the most appropriate classification is Governance Information (CGR).
2025-09-30 Chinese
关于筹划发行H股股票并在香港联合交易所有限公司上市的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (1087 characters) regarding the company's plan to issue H shares and list on the Hong Kong Stock Exchange. It includes references to board resolutions and regulatory approvals needed but does not contain any financial statements or detailed financial data. It is a forward-looking notice about a capital market transaction, specifically about a planned share issuance and listing. This fits the definition of a Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not a report publication announcement since it does not mention an attached report or provide a link to a report. Therefore, the appropriate classification is CAP with high confidence.
2025-09-30 Chinese
关于调整第三届董事会专门委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the adjustment of members of the company's board committees, specifically the nomination committee and the remuneration and assessment committee. It mentions the board meeting date and the changes in committee composition. There is no financial data, no mention of annual or quarterly reports, no voting results, and no other types of filings. The content clearly relates to changes in the company's board or management structure. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused on board committee changes, confirming this classification.
2025-09-30 Chinese
董事会战略委员会工作细则（H股发行上市后适用）
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Strategic Committee Working Rules" of a company, detailing the committee's composition, responsibilities, decision-making procedures, meeting rules, and governance structure. It references company law, listing rules, and internal governance but does not contain financial data, audit information, or report results. It is a governance document outlining internal board committee rules rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR). The document length is 3694 characters, which is consistent with a detailed governance policy document rather than a brief announcement or report publication notice.
2025-09-30 Chinese
董事会提名委员会工作细则（H股发行上市后适用）
Governance Information Classification · 100% confidence The document is titled as the "Board Nomination Committee Working Rules" of a company, detailing the structure, responsibilities, procedures, and governance of the board nomination committee. It references company law, stock exchange listing rules, and internal company articles. The content is about governance practices and internal rules related to board nominations and management appointments. There is no financial data, no report publication announcement, no voting results, no executive compensation details, and no regulatory filing or legal proceeding updates. This document fits the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2025-09-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.